In previous work,we developed polymeric nanoparticles with a surfacecoating of the human DR5 antibody AMG 655 and demonstrated their superiorantitumor effects versus the antibody in free format using human xenografts., Despite these promising outcomes, there remains a need to investigatehow these effects translate to different DR5 agonists and in morecomplete and syngeneic tumor microenvironments. The gene discussed is TNFRSF10B; the disease is neoplasm.